Comparison

SARS-CoV-2 (COVID-19) Envelope Antibody (biotin)

Item no. PRS-3531-biotin-0.1mg
Manufacturer ProSci
Amount 0.1 mg
Quantity options 0.02 mg 0.1 mg
Category
Type Antibody Polyclonal
Format Liquid
Applications IHC, ELISA
Specific against Virus
Host Rabbit
Isotype IgG
Conjugate/Tag Biotin
Citations Gorbalenya. bioRxiv: 2020.
Hui et al. Int J Infect Dis. 2020;91:264-266.
Pervushin et al. PLoS Pathog. 2009; 5(7): e1000511.
Nuovo GJ et al. Cytologic and molecular correlates of SARS-CoV-2 infection of the nasopharynx. Ann Diagn Pathol. 2020; 48:151565. doi: 10.1016/j.anndiagpath.2020.151565. PMID: 32659620
Magro C, Mulvey JJ, Laurence J, Sanders S, Crowson N, Grossman M, Harp J, Nuovo G. The differing pathophysiologies that underlie COVID-19 associated perniosis and thrombotic retiform purpura: a case series. Br J Dermatol. 2020; 22:10.1111/bjd.19415. doi: 10.1111/bjd.19415. PMID: 32779733
Nuovo G, Tili E, Suster D, Matys E, Hupp L, Magro C. Strong homology between SARS-CoV-2 envelope protein and a Mycobacterium sp. antigen allows rapid diagnosis of Mycobacterial infections and may provide specific anti-SARS-CoV-2 immunity via the BCG vaccine. Ann Diagn Pathol. 2020; 48:151600. doi: 10.1016/j.anndiagpath.2020.151600. PMID: 32805515
Ko, et al. Discordant anti-SARS-CoV-2 spike protein and RNA staining in cutaneous perniotic lesions suggests endothelial deposition of cleaved spike protein. J Cutan Pathol . 2021 Jan;48(1):47-52. doi: 10.1111/cup.13866. Epub 2020 Oct 1.PMID: 32895985 
Magro, et al. Docked severe acute respiratory syndrome coronavirus 2 proteins within the cutaneous and subcutaneous microvasculature and their role in the pathogenesis of severe coronavirus disease 2019. Hum Pathol. 2020 Dec;106:106-116. doi: 10.1016/j.humpath.2020.10.002. Epub 2020 Oct 12.PMID: 33058948
Magro, et al. The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series. Br J Dermatol. 2020 Jul 22;10.1111/bjd.19415. doi: 10.1111/bjd.19415PMID: 32779733
Mulvey, et al. Analysis of complement deposition and viral RNA in placentas of COVID-19 patients. Ann Diagn Pathol. 2020 Jun;46:151530. doi: 10.1016/j.anndiagpath.2020.151530. Epub 2020 Apr 25.PMID: 32387855
Rotman, et al. Concomitant calciphylaxis and COVID-19 associated thrombotic retiform purpura. Skeletal Radiol. 2020 Nov;49(11):1879-1884. doi: 10.1007/s00256-020-03579-6. Epub 2020 Aug 26.PMID: 32844243
NCBI E
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Alias SARS-CoV-2 (COVID-19,2019-nCoV) Envelope Antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),Envelope protein,E protein
Shipping Condition Cool pack
Available
Manufacturer - Type
Primary Antibodies
Shipping Temperature
Blue Ice
Storage Conditions
SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope antibody can be stored at 4 ˚ C for three months and -20 ˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Manufacturer - Research Area
Infectious Disease, COVID-19
Background
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3).
By Type
Infectious Disease, COVID-19
Badges
Trial Size, New
Modifications
None
Protein Gi #
1791269092
Purification
SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope Antibody is affinity chromatography purified via peptide column.
Isoforms
SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope has one isoform (75aa).
Concentration
1 mg/mL
Buffer
SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope Antibody is supplied in PBS containing 0.02% sodium azide.
Application Note
IHC: 2 μ g/mL
Antibody validated: Immunohistochemistry in COVID-19 patient samples. All other applications and species not yet tested.
Homology
Predicted reactivity based on immunogen sequence: SARS-CoV Envelope proteins: (100%)
Immunogen
Anti-SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope antibody (3531) was raised against a peptide corresponding to 10 amino acids near the amino terminus of SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope protein.

The immunogen is located within the first 50 amino acids of SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope.
Clonality
Polyclonal
NCBI Official Name
envelope protein
NCBI Organism
Wuhan seafood market pneumonia virus
Disclaimer
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
User Note
Optimal dilutions for each application to be determined by the researcher.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 0.1 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close